Why Is Foghorn Therapeutics (FHTX) Stock Down -29.82% Today?
Key Takeaways
- Shares plunged roughly 29.8% to about $2.05, down from the prior session's close of $2.92.
- Primary catalyst: Foghorn and Eli Lilly terminated their oncology collaboration and discontinued FHD-909 after Phase 1 data showed insufficient clinical efficacy.
- Secondary drivers: A wave of analyst downgrades and price-target cuts, plus a roughly 40% workforce reduction.
- Broader context: The decline compounds an 18% slump the previous session, pushing shares near record lows and deepening a year-to-date sell-off of roughly 60%.
- What traders are watching next: Execution of the company's pivot to its wholly owned pipeline and its extended cash runway into the second half of 2029.
Opening Summary
Foghorn Therapeutics Inc. (FHTX), a clinical-stage biotechnology company developing precision medicines that target the chromatin regulatory system, suffered another sharp sell-off in today's session. The stock fell approximately 29.8% to about $2.05, compared with a prior close of $2.92, extending steep losses after the company announced it would end its cancer-drug collaboration with Eli Lilly (LLY) and discontinue its lead partnered program, FHD-909.
Catalyst: End of the Eli Lilly Collaboration
The move was driven primarily by the termination of Foghorn's partnership with Eli Lilly. Following a review of Phase 1 dose-escalation data, the two companies decided not to advance FHD-909, an oral SMARCA2 degrader, into further clinical development. The companies also shelved a related selective SMARCA2 degrader program, effectively ending the collaboration that began in December 2021 under a deal that included $300 million upfront and an $80 million equity investment from Lilly.
While FHD-909 demonstrated a favorable safety profile and achieved drug exposures that exceeded preclinical targets, the treatment did not produce sufficient clinical efficacy to justify continued development. Because the Lilly partnership represented a meaningful portion of the company's valuation and future milestone potential, its dissolution removed a key pillar of the investment thesis, triggering aggressive selling across the session.
Analyst Downgrades and Price-Target Cuts
The clinical setback was compounded by a rapid repricing on Wall Street. Wedbush downgraded the stock to Neutral from Outperform and slashed its price target to $2 from $10, stating that the Lilly collaboration had been a major component of its bullish thesis. Several other firms followed suit, with BTIG, TD Cowen, Citigroup, and Citizens all lowering their ratings or moving to a more cautious stance.
Some analysts maintained positive ratings while cutting targets. Guggenheim and Stifel each lowered their price targets to $5 from $12, and H.C. Wainwright reduced its target to $5 from $13 while keeping a Buy rating, pointing to potential in the company's EP300 degrader program for blood cancers. The collective retreat in targets and ratings reinforced the negative market reaction.
Restructuring and Pipeline Pivot
Foghorn also announced a restructuring that includes cutting approximately 40% of its workforce as it redirects resources toward wholly owned programs. Those include a selective EP300 degrader, a selective CBP degrader, an oral immunology and inflammation program, and its induced-proximity platform. Management said the reprioritization and cost reductions are expected to extend the company's cash runway into the second half of 2029.
While the pivot preserves capital and refocuses the pipeline, investors responded to the loss of the Lilly-funded programs and the headcount reduction as a sign of diminished near-term optionality, further weighing on the share price.
Market Context and Trading Activity
Trading volume was exceptionally heavy, reflecting the significance of the announcement. In the prior session, more than 9.1 million shares changed hands versus a typical average of roughly 377,000, and the elevated activity carried into today as the sell-off accelerated. The stock has been trading at or near 52-week lows, well below its 50-day and 200-day moving averages, indicating broken technical support and a broad-based loss of momentum.
The decline diverged from the broader market and from the biotech sector more generally, underscoring that the move was company-specific rather than a symptom of wider macro weakness. The stock's negative momentum reflects investor revaluation of a pipeline that has now lost its flagship partnered asset.
What Comes Next for FHTX
Looking ahead, the focus shifts to Foghorn's ability to advance its wholly owned programs without a major partner. The company is targeting an Investigational New Drug (IND) application for its EP300 degrader program in 2027, with an initial focus on multiple myeloma and diffuse large B-cell lymphoma. Preclinical data has shown encouraging anti-tumor activity, but the program remains years from potential commercialization.
Key risks include execution of the restructuring, the absence of partnership milestone revenue, and the inherent uncertainty of early-stage drug development. Upcoming earnings, updates on the reprioritized pipeline, and any new collaboration announcements will be closely monitored. The extended cash runway provides some cushion, but the path to restoring investor confidence hinges on delivering new clinical data.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots that are currently performing at the highest levels under prevailing market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with each bot varying by strategy, timeframe, performance metrics, and traded symbols. Only the strongest performers are featured in this dedicated section, helping traders discover automated strategies aligned with the present market environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
FHTX's RSI Indicator stays in oversold zone for 22 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +2.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where FHTX advanced for three days, in 237 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
FHTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
FHTX moved below its 50-day moving average on September 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for FHTX crossed bearishly below the 50-day moving average on September 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
The 50-day moving average for FHTX moved below the 200-day moving average on October 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FHTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for FHTX entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. FHTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: FHTX's P/B Ratio (2000.000) is very high in comparison to the industry average of (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (7.553) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FHTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement